Syngeneic |
• Not artificial |
• Lack of diverse cancer cell line and heterogeneity |
[15,17,18,19,20,21,22] |
• Easy to utilize |
• Mostly chemical induced cancer cell line |
• Rapid tumor development |
• Tumor does not develop from normal cells or develop in a natural microenvironment |
• Reproducible |
• Mouse and human immune systems have vital differences |
• Low in cost |
• Might cause a vaccination effect |
• Tumor can be accurately monitored without difficulty |
• Human HCC cannot be completely recapitulated by mouse cancer cells in terms of the complexity, histology, and natural carcinogenesis characteristics |
• Non-immunogenic |
• Short experimental window |
Chemotoxic agent |
• Easy to work with |
• Tumor formation is not initiated by chronic inflammation |
[18,19,20,21,23] |
• Sporadic cancer development |
|
• Higher heterogeneity |
• Difficult to monitor a tumor |
• Tumors generally progress in a natural microenvironment and develop from normal cells |
• Variability in the time for tumor progression |
• Available to incorporate with other approaches for tumor induction |
• Larger sample sizes are needed for data interpretation due to the high heterogeneity |
GEMM |
• Encompasses natural tumor microenvironments |
• Longer latency and time for tumor development |
[15,17,18,19,20,21,22] |
• The genetic and histopathological aspects of all stages of cancer can be recapitulated |
• Difficult to monitor a tumor |
|
• Low immunogenicity |
|
• Costly and challenging for breeding and gene manipulation |
• Tumors develop from normal cells |
• Homogeneous in the genomic aspect |
Humanized |
CD34+
|
• Immediately available for experiment |
• 4–8 weeks of experimental window |
[15,21,24,25] |
• The complex human immune system and human HCC can be recapitulated |
• Difficult to set up |
PBL |
• The entire complex human immune system can be established |
• 10-12 weeks are required for HSC engraftment |
[15,21,24,25] |
|
• Difficult to set up |
• Human HCC can be recapitulated |
• High in cost |